Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

• Main Authors: Jianling Bi (Author), Garima Dixit (Author), Yuping Zhang (Author), Eric J. Devor (Author), Haley A. Losh (Author), Andreea M. Newtson (Author), Kristen L. Coleman (Author), Donna A. Santillan (Author), Thorsten Maretzky (Author), Kristina W. Thiel (Author), Kimberly K. Leslie (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemothe...